

## Systematic Search of the Literature

PubMed (National Library of Medicine, NCBI)

278 records retrieved March 15, 2024

NOTE: This search strategy was conducted to identify studies examining follow-up after inconclusive or abnormal results of procedures screening for colorectal or prostate cancer, in addition to breast cancer.

((("Mammography"[Mesh] OR "Prostate-Specific Antigen"[Mesh] OR "Colonoscopy"[Mesh] OR "Colonography, Computed Tomographic"[Mesh] OR mammogra\*[tiab] OR breast tomosynthes\*[tiab] OR prostate specific antigen[tiab] OR colonoscop\*[tiab] OR sigmoidoscop\*[tiab] OR colonograph\*[tiab] OR fecal occult blood test\*[tiab] OR faecal occult blood test\*[tiab] OR fecal immunochemical test\*[tiab] OR faecal immunochemical test\*[tiab] OR FIT-DNA test\*[tiab]))

OR

("Early Detection of Cancer"[Mesh] OR "Mass Screening"[Mesh:NoExp] OR cancer screening[tiab] OR cancer diagnosis[tiab] OR diagnostic evaluation\*[tiab] OR cancer early detection[tiab] OR early detection of cancer[tiab] OR early diagnosis of cancer[tiab] OR cancer early diagnosis[tiab]) AND ("Breast Neoplasms"[Mesh] OR "Colorectal Neoplasms"[Mesh] OR "Prostatic Neoplasms"[Mesh] OR ((breast[tiab] OR colorectal[tiab] OR colon[tiab] OR colonic[tiab] OR rectal[tiab] OR rectum[tiab] OR prostate[tiab] OR prostatic[tiab]) AND (cancer\*[tiab] OR carcinoma\*[tiab] OR adenocarcinoma\*[tiab] OR malignanc\*[tiab] OR tumor\*[tiab] OR tumour\*[tiab] OR neoplasm\*[tiab])))

AND

(abnormal\*[tiab] OR (positive[tiab] AND (fecal occult blood test\*[tiab] OR faecal occult blood test\*[tiab] OR fecal immunochemical test\*[tiab] OR faecal immunochemical test\*[tiab] OR FIT-DNA test\*[tiab])) OR (elevated[tiab] AND prostate-specific antigen[tiab]))

AND

("Delayed Diagnosis"[Mesh] OR "Time Factors"[Mesh] OR delay\*[tiab] OR overdue[tiab] OR timely[tiab] OR missed[tiab] OR inadequate follow up[tiab] OR failure to follow up[tiab] OR appropriate follow up[tiab] OR lack of follow up[tiab])

AND

("Follow-Up Studies"[Mesh] OR follow up[tiab] OR followup[tiab])

AND

2010[pdat]:2024[pdat]

AND

English[lang]

## Literature Included in Environmental Scan

1. Doubeni CA, Gabler NB, Wheeler CM, et al. Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. *CA Cancer J Clin*. 2018;68(3):199-216. doi:10.3322/caac.21452. PMID: 29603147.
2. Reece JC, Neal EFG, Nguyen P, McIntosh JG, Emery JD. Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review. *BMC Cancer*. 2021;21(1):373. Published 2021 Apr 7. doi:10.1186/s12885-021-08100-3. PMID: 3382747.
3. Olivotto IA, Gomi A, Bancej C, et al. Influence of delay to diagnosis on prognostic indicators of screen-detected breast carcinoma. *Cancer*. 2002;94(8):2143-2150. doi:10.1002/cncr.10453. PMID: 12001110.
4. Ganry O, Peng J, Dubreuil A. Influence of abnormal screens on delays and prognostic indicators of screen-detected breast carcinoma. *J Med Screen*. 2004;11(1):28-31. doi:10.1177/096914130301100107. PMID: 15006111.
5. Van Breest Smallenburg V, Nederend J, Voogd AC, et al. Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands. *Br J Cancer*. 2013;109(1):242-248. doi:10.1038/bjc.2013.253. PMID: 23695018.
6. Lameijer JRC, Voogd AC, Pijnappel RM, et al. Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands. *Br J Cancer*. 2020;123(2):325-332. doi:10.1038/s41416-020-0870-2. PMID: 32390006.
7. Toss A, Isca C, Venturelli M, et al. Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era. *ESMO Open*. 2021;6(2):100055. doi:10.1016/j.esmoop.2021.100055. PMID: 33582382.
8. DeGroff A, Royalty JE, Howe W, et al. When performance management works: a study of the National Breast and Cervical Cancer Early Detection Program. *Cancer*. 2014;120 Suppl 16(Suppl 16):2566-2574. doi:10.1002/cncr.28817. PMID: 25099899.
9. Rauscher GH, Murphy AM, Orsi JM, Dupuy DM, Grabler PM, Weldon CB. Beyond the mammography quality standards act: measuring the quality of breast cancer screening programs. *AJR Am J Roentgenol*. 2014;202(1):145-151. doi:10.2214/AJR.13.10806. PMID: 24261339.
10. Rauscher GH, Tossas-Milligan K, Macarol T, Grabler PM, Murphy AM. Trends in Attaining Mammography Quality Benchmarks With Repeated Participation in a Quality Measurement Program: Going Beyond the Mammography Quality Standards Act to Address Breast Cancer Disparities. *J Am Coll Radiol*. 2020;17(11):1420-1428. doi:10.1016/j.jacr.2020.07.019. PMID: 32771493.
11. Murphy DR, Meyer AND, Vaghani V, et al. Electronic Triggers to Identify Delays in Follow-Up of Mammography: Harnessing the Power of Big Data in Health Care. *J Am Coll Radiol*. 2018;15(2):287-295. doi:10.1016/j.jacr.2017.10.001. PMID: 29102539.

12. Meyer AND, Singh H, Zimolzak AJ, et al. Cancer Evaluations During the COVID-19 Pandemic: An Observational Study Using National Veterans Affairs Data. *Am J Prev Med.* 2022;63(6):1026-1030. doi:10.1016/j.amepre.2022.07.004. PMID: 36055880.
13. Haas JS, Atlas SJ, Wright A, et al. Multilevel Follow-up of Cancer Screening (mFOCUS): Protocol for a multilevel intervention to improve the follow-up of abnormal cancer screening test results. *Contemp Clin Trials.* 2021;109:106533. doi:10.1016/j.cct.2021.106533. PMID: 34375748.
14. Atlas SJ, Tosteson ANA, Wright A, et al. A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial. *JAMA.* 2023;330(14):1348-1358. doi:10.1001/jama.2023.18755. PMID: 37815566.
15. Diamond CJ, Laurentiev J, Yang J, et al. Natural Language Processing to Identify Abnormal Breast, Lung, and Cervical Cancer Screening Test Results from Unstructured Reports to Support Timely Follow-up. *Stud Health Technol Inform.* 2022;290:433-437. doi:10.3233/SHTI220112. PMID: 35673051.
16. Wernli KJ, Aiello Bowles EJ, Haneuse S, Elmore JG, Buist DS. Timing of follow-up after abnormal screening and diagnostic mammograms. *Am J Manag Care.* 2011;17(2):162-167. PMID: 21473665.
17. McCarthy AM, Kim JJ, Beaber EF, et al. Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. *Am J Prev Med.* 2016;51(4):507-512. doi:10.1016/j.amepre.2016.03.017. PMID: 27132628.
18. Tosteson AN, Beaber EF, Tiro J, et al. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. *J Gen Intern Med.* 2016;31(4):372-379. doi:10.1007/s11606-015-3552-7. PMID: 26658934.
19. Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS. Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups. *Cancer.* 2017;123(18):3468-3475. doi:10.1002/cncr.30756. PMID: 28603859.
20. Barlow WE, Beaber EF, Geller BM, et al. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. *J Natl Cancer Inst.* 2020;112(3):238-246. doi:10.1093/jnci/djz137. PMID: 31292633.
21. Khoong EC, Rivadeneira NA, Pacca L, et al. Extent of Follow-Up on Abnormal Cancer Screening in Multiple California Public Hospital Systems: A Retrospective Review. *J Gen Intern Med.* 2023;38(1):21-29. doi:10.1007/s11606-022-07657-4. PMID: 35641722.
22. Platt S, Montgomery GH, Schnur JB, Margolies L. BI-RADS-0 Screening Mammography: Risk Factors That Prevent or Delay Follow-Up Time to Diagnostic Evaluation. *J Am Coll Radiol.* 2022;19(11):1262-1268. doi:10.1016/j.jacr.2022.07.006. PMID: 35985631.
23. Oluyemi ET, Grimm LJ, Goldman L, et al. Rate and Timeliness of Diagnostic Evaluation and Biopsy After Recall From Screening Mammography in the National Mammography Database. *J Am Coll Radiol.* 2024;21(3):427-438. doi:10.1016/j.jacr.2023.09.002. PMID: 37722468.